Finanzas de Odyssey Therapeutics Inc (ODTX)ODTXOdyssey Therapeutics Inc

In the context of the broader market, ODTX competes directly with industry leaders such as JBIO and KURA. With a market capitalization of $825.16M, it holds a significant position in the sector. When comparing efficiency, ODTX's gross margin of N/A stands against JBIO's N/A and KURA's 98.84%. Such benchmarking helps identify whether Odyssey Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Odyssey Therapeutics has shown a gross margin of 100% in previous quarters, but recent quarters have reported zero gross profit, reflecting challenges in revenue generation. The company reported a net loss of $52.8 million in Q2 2026, up from $41.2 million a year earlier, indicating increased financial losses.